ASH 2020 | Achieving undetectable MRD with ibrutinib plus venetoclax for CLL
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses updated data from a Phase II trial (NCT02756897) of ibrutinib and venetoclax for patients with chronic lymphocytic leukemia (CLL). Results were presented with a median follow-up of 36.3 months with a focus on measurable residual disease (MRD). The study found that 50% conversion of bone marrow MRD+ to undetectable MRD was achieved from cycle 12 to 24 with ongoing combination therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Nitin Jain, MD, has received research funding from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Aprea Therapeutics and Fate Therapeutics; and has participated in advisory boards or received honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Adaptive Biotechnologies, Servier, Precision Biosciences, Beigene, TG Therapeutics and ADC Therapeutics.
